Furui Co.,Ltd(SZ:300049)2022-12-04 09:30Company Overview - Founded on November 26, 1998, focusing on liver disease pharmaceuticals, diagnostic equipment, and related medical services [2] - Achieved full licensing in the health industry, covering medical devices, therapeutic drugs, insurance, offline and online medical institutions, and health management [2] - Main product, Compound Turtle Shell Soft Liver Tablets, is the first anti-liver fibrosis drug approved by the National Medical Products Administration, with a market share exceeding 25% [2] Business Segments Pharmaceutical Business - Actively adjusting sales models to enhance product image and explore "drug benefit management" to improve sales resources and bargaining power [3] - The company aims to provide better health management services for liver disease patients while increasing profit margins and risk resistance [3] Diagnostic Equipment - Main product, FibroScan series, is the first non-invasive device using transient elastography technology for liver stiffness measurement, certified by CE, FDA, and CFDA [3] - In 2019, launched two new products, FibroScan HANDY and FibroScan Q, to meet diverse market needs [3] - Plans to collaborate with international pharmaceutical companies to enhance global clinical application of FibroScan [3] Medical Services - Obtained an internet hospital license in early 2020, offering comprehensive online services including consultations, prescriptions, and home delivery [3] - Focus on chronic liver disease management through online follow-ups and health education to improve patient compliance and reduce overall medical costs [3] Market Impact and Strategy - The COVID-19 pandemic has had mixed effects on company performance; plans to increase investor communication and funding for new business initiatives [4] - The French subsidiary's performance showed growth potential despite pandemic-related constraints [4] - The company is developing a fee-for-service model for diagnostic instruments, which is expected to become a significant revenue source in the long term [4] Sales Performance - In 2019, over 50% of diagnostic equipment sales revenue came from the U.S., with Europe contributing about 20% [6] - China accounted for approximately half of the Asian market sales [6] Future Directions - Emphasis on developing products suitable for grassroots medical institutions to meet diverse market demands [6] - Plans to enhance internet hospital operations and support community hospitals in providing quality medical services [7] - Continuous investment in R&D for more intelligent liver disease diagnostic products [6]